Compare IRIX & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRIX | PASG |
|---|---|---|
| Founded | 1989 | 2017 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0M | 14.6M |
| IPO Year | 1996 | 2020 |
| Metric | IRIX | PASG |
|---|---|---|
| Price | $0.72 | $3.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | ★ 702.7K | 13.3K |
| Earning Date | 11-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.85 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,593,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.58 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.61 | $3.29 |
| 52 Week High | $1.65 | $20.00 |
| Indicator | IRIX | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 43.97 | 38.04 |
| Support Level | $0.70 | $3.29 |
| Resistance Level | $1.00 | $5.03 |
| Average True Range (ATR) | 0.06 | 0.25 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 2.19 | 15.87 |
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.